Abstract: The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

Abstract: The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection including characteristic values of at least five metabolites, a data storage medium including data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

Abstract: The present invention pertains to the field of diagnostics for iron adsorption disorder or impaired energy metabolism and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing iron adsorption disorder or impaired energy metabolism. It also relates to a method for determining whether a compound is capable of inducing such iron adsorption disorder or impaired energy metabolism in a subject and to a method of identifying a drug for treating iron adsorption disorder or impaired energy metabolism. Furthermore, the present invention relates to a device and a kit for diagnosing iron adsorption disorder or impaired energy metabolism.

Abstract: The present invention pertains to the field of diagnostics for hematopoietic toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing hematopoietic toxicity. It also relates to a method for determining whether a compound is capable of inducing such hematopoietic toxicity in a subject and to a method of identifying a drug for treating hematopoietic toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing hematopoietic toxicity.

Abstract: The present invention pertains to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

Abstract: The present invention pertains to the field of diagnostics for hyperthyroidism and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing hyperthyroidism. It also relates to a method for determining whether a compound is capable of inducing such hyperthyroidism in a subject and to a method of identifying a drug for treating hyperthyroidism. Furthermore, the present invention relates to a device and a kit for diagnosing hyperthyroidism.

Abstract: The present invention pertains to the field of diagnostics for bone disorders and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing a bone disorder. It also relates to a method for determining whether a compound is capable of inducing such a bone disorder in a subject and to a method of identifying a drug for treating a bone disorder. Furthermore, the present invention relates to a device and a kit for diagnosing a bone disorder.

Abstract: The present invention pertains to the field of diagnostics for liver disorders and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver disorders. It also relates to a method for determining whether a compound is capable of inducing such liver disorders in a subject and to a method of identifying a drug for treating liver disorders. Furthermore, the present invention relates to a device and a kit for diagnosing liver disorders.

Abstract: The present invention pertains to the field of diagnostics for an endocrine disease or disorder and assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing an endocrine disease or disorder. It also relates to a method for determining whether a compound is capable of inducing such an endocrine disease or disorder in a subject and to a method of identifying a drug for treating an endocrine disease or disorder. Furthermore, the present invention relates to a device and a kit for diagnosing an endocrine disease or disorder.

Abstract: The present invention pertains to the field of diagnostics for kidney toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing kidney toxicity. It also relates to a method for determining whether a compound is capable of inducing such kidney toxicity in a subject and to a method of identifying a drug for treating kidney toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing kidney toxicity.

Abstract: The present invention pertains to the field of diagnostics for gonadal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing gonadal toxicity. It also relates to a method for determining whether a compound is capable of inducing such gonadal toxicity in a subject and to a method of identifying a drug for treating gonadal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing gonadal toxicity.

Abstract: The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing the pro-pathological effect of compounds which are inducing liver enzymes. It also relates to a method of determining whether a compound is capable of exhibiting pro-pathological effects on the liver by enzyme induction in a subject and to a method of identifying a drug for treating the pro-pathological effect of liver enzyme induction. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five analytes, a data storage medium comprising said data collection, and a system and a device for diagnosing the pro-pathological effect of liver enzyme induction.

Abstract: The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

Abstract: The present invention pertains to the field of toxicological assessments of risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection of characteristic values of at least five metabolites, a data storage medium for the data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

Abstract: The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver toxicity. It also relates to a method of determining whether a compound is capable of inducing such liver toxicity in a subject and to a method of identifying a drug for treating liver toxicity. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing liver toxicity. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing liver toxicity in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed.

Abstract: The present invention relates to a method for diagnosing hemolytic anemia or a predisposition thereof. It also relates to a method of determining whether a compound is capable of inducing hemolytic anemia in a subject and to a method of identifying a drug for treating hemolytic anemia. Furthermore, the present invention relates to a data collection comprising characteristic values of metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing hemolytic anemia. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing hemolytic anemia in a subject.

Abstract: The present invention relates to methods for evaluating biomarkers. In particular, the invention relates to a method for establishing at least one pattern for at least one pre-defined effector having at least one effect on a biological system, which effect is capable of being determined, to a method of establishing a class of effectors for a pre-defined effect or group of effects, to a method for identifying at least one effect of a pre-defined effector and to a computer program and a computer adapted to carry out these methods.

Abstract: The present invention relates to a method for diagnosing thyroid disorders. It also relates to a method of determining whether a compound is capable of inducing a thyroid disorder in a subject and to a method of identifying a drug for treating a thyroid disorder. Furthermore, the present invention relates a device for diagnosing a thyroid disorder and diagnostic uses.

Abstract: The present invention relates to sulfonamide compounds of formula (I) wherein R1 is H, halogen, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C4-alkyl, C1-C6-alkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C1-C6-alkylthio, C2-C6-alkenylthio, C2-C6-alkynylthio, C1-C6-haloalkyl or C1-C6-haloalkoxy; R2 and R3 are H, halogen, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C4-alkyl, C1-C6-alkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C1-C6-alkylthio, C2-C6-alkenylthio, C2-C6-alkynylthio, C1-C6-haloalkyl or C1-C6-haloalkoxy; or R2 together with R3 form a fused 5 or 6-membered carbocycle or heterocycle; R4 is halogen, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-haloalkyl, C1-C6-haloalkoxy, C1-C6-haloalkylthio, C1-C6-haloalkylsulfinyl or C1-C6-haloalksulfonyl; n is 0, 1, 2 or 3; R5 is phenyl or a 5- or 6-membered heterocycle; X is O or NRx, wherein Rx is H, C1-C6

Abstract: The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver toxicity. It also relates to a method of determining whether a compound is capable of inducing such liver toxicity in a subject and to a method of identifying a drug for treating liver toxicity. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing liver toxicity. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing liver toxicity in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed.